Asian alliance hones Otsuka's focus and feeds Kyowa Kirin's regional ambitions
This article was originally published in Scrip
Otsuka Pharmaceutical has entered into its second major alliance in less than eight months, this time with fellow Japanese firm Kyowa Hakko Kirin in a deal for diabetes and oncology that on closer examination aligns well with both companies' strategic aims.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.